Lsl Pharma Group(TSXV) LSL

Market CapCA$37.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-61%
5 YearN/A
1 Year-16%
1 Month-11%
CA$0.30
+1.70%
+0.01Today
Lsl Pharma Group last closing stock price
MetricPriceDate
Last closeCAD 0.302026-10-07
Lsl Pharma Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.67%CAD 0.302026-09-30
1 month-10.61%CAD 0.332026-09-04
3 month-9.23%CAD 0.332026-07-09
Year to date-15.71%CAD 0.352025-12-31
1 year-15.71%CAD 0.352025-10-07
3 year-31.4%CAD 0.432023-10-05
Since inception-60.67%CAD 0.752023-03-02

Lsl Pharma Group Financials at a Glance

Market Cap

CA$37.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$41.83

Net Income (TTM)

-CA$7.34

EPS (TTM)

-CA$0.06

P/E Ratio

-5.03

Dividend

CA$0.00

Beta (Volatility)

0.12 (Low)

Price

CA$0.30

Volume

47,500

Open

CA$0.30

Previous Close

CA$0.30

Daily Range

CA$0.30 - CA$0.30

52-Week Range

CA$0.28 - CA$0.56

Estimated Earnings Date

Nov 18, 2026

LSL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lsl Pharma Group

LSL Pharma Group Inc. is a pharmaceutical company focused on the development, manufacture, and distribution of natural health products and dietary supplements. The company also specializes in sterile ophthalmic pharmaceutical products, catering to a diverse market in the healthcare sector.

Products and Services
  • Natural health products in solid dosage forms
  • Dietary supplements tailored for various health needs
  • Sterile ophthalmic pharmaceutical products for eye care
Growth Outlook
  • Recent IPO in March 2023 indicates strong market interest
  • Expansion into new product lines expected to drive revenue growth
  • Increasing demand for natural health products supports long-term potential
Financial Highlights
  • Market capitalization of CAD 40.55 million reflects growth potential
  • Stock price range between CAD 0.30 and CAD 0.56 shows stability
  • Volume of 50,000 shares indicates active trading interest
LSL Pharma Group Inc. operates in a competitive pharmaceutical landscape, focusing on natural health and dietary products. The recent IPO signifies a strategic move to enhance visibility and attract investment. The company's diverse product offerings cater to a growing consumer demand for health-focused solutions, particularly in the natural segment. With a solid market capitalization and active trading volume, LSL Pharma Group Inc. presents an intriguing opportunity for investors interested in the healthcare sector. The company's commitment to innovation and expansion positions it well for future growth, making it a noteworthy consideration in the pharmaceutical industry.
AI Generated • Sep 17, 2026

Industry

Personal Products

Sector

Consumer Staples

CEO

François Roberge

Website

www.groupelslpharma.com

Headquarters

Boucherville, QC J4B 0G6, CA

LSL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-31.63%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-19.88%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

CA$37.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

126.73M

Volume

47.50K

Avg. Volume

35.92K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Lsl Pharma Group Performance Analysis

Lsl Pharma Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31CAD 0N/A
20232023-12-31CAD 10,028,000N/A
20242024-12-31CAD 17,748,00077.0%
20252025-12-31CAD 28,744,00062.0%
Lsl Pharma Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31CAD -0.09N/A
20232023-12-31CAD -0.1117.4%
20242024-12-31CAD 0.03N/A
20252025-12-31CAD -0.02N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$14.63

+2.0%

Gross Profit

CA$1.31

+0.7%

Gross Margin

8.95%

+0.4%

Market Cap

CA$37.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-CA$2.24

+5.8%

EBITDA

-CA$0.03

-0.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$51.56

+55.9%

Total Debt

CA$50.59

+1.8%

Accounts Receivable

CA$7.92

+1.5%

Inventory

CA$17.07

+1.4%

Long Term Debt

CA$38.17

+2.2%

Short Term Debt

CA$12.42

+1.2%

Return on Assets

-9.85%

-1.4%

Return on Invested Capital

-16.75%

+0.7%

Free Cash Flow

-CA$0.01

-0.0%

Operating Cash Flow

CA$0.40

+0.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CSCI.TOCOSCIENS Biopharma Inc.
CA$9.89+7.73%
EBM.VEastwood Bio-Medical Canada Inc.
CA$1.73-12.18%
MDP.TOMedexus Pharmaceuticals Inc.
CA$4.99+2.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$107.08-5.34%
NVDANvidia
$230.48-2.94%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
BITOProShares Trust - ProShares Bitcoin ETF
$10.93-1.88%

Questions About LSL

What is the current price of Lsl Pharma Group?

Lsl Pharma Group is trading at CA$0.30 per share.

What is the 52-week range for Lsl Pharma Group?

Over the past 52 weeks, Lsl Pharma Group has traded between CA$0.28 and CA$0.56.

How much debt does Lsl Pharma Group have?

As of the most recent reporting period, Lsl Pharma Group reported total debt of CA$50.59M.

How much cash does Lsl Pharma Group have on hand?

Lsl Pharma Group reported CA$967.00K in cash and cash equivalents in its most recent financial results.

What is Lsl Pharma Group’s dividend yield?

Lsl Pharma Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services